Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIM-AF
NCT03603912Phase 4Active, not recruiting
- Start
- Aug 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liquid metformin (Aspargo Labs) in Atrial fibrillation (AFib) (5 arms). Primary endpoint: Change in AF burden at 1 year. Started Aug 2018; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03603912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603912.